Last reviewed · How we verify
Urfamicin — Competitive Intelligence Brief
unknown
thiamphenicol glycinate
Infectious Disease
Live · refreshed every 30 min
Target snapshot
Urfamicin (thiamphenicol glycinate). Urfamicin works by inhibiting protein synthesis in bacteria.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Urfamicin TARGET | thiamphenicol glycinate | unknown | thiamphenicol glycinate |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (thiamphenicol glycinate class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Urfamicin CI watch — RSS
- Urfamicin CI watch — Atom
- Urfamicin CI watch — JSON
- Urfamicin alone — RSS
- Whole thiamphenicol glycinate class — RSS
Cite this brief
Drug Landscape (2026). Urfamicin — Competitive Intelligence Brief. https://druglandscape.com/ci/thiamphenicol-glycinate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing